```
= > e collagenase
E1      2336    COLLAGEN/BI
E2         1    COLLAGENAN/BI
E3       293 --> COLLAGENASE/BI
E4         1    COLLAGENCONTIG/BI
E5         6    COLLAGENE/BI
E6         5    COLLAGENIC/BI
E7         2    COLLAGENOL/BI
E8         2    COLLAGENOLYTIC/BI
E9         1    COLLAGENON/BI
E10       14    COLLAGENOUS/BI
E11       90    COLLAGENS/BI
E12        2    COLLAGENVI/BI
= > s e3
L2   ANSWER 1 OF 293  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   604952-46-7  REGISTRY
CN   Collagenase (Mycoplasma gallisepticum strain Rlow gene MGA_0839)
     (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   GenBank AAP56476
CN   GenBank AAP56476 (Translated from: GenBank AE016967)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   GenBank
LC   STN Files:  CA, CAPLUS

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
          1 REFERENCES IN FILE CA (1907 TO DATE)
          1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
= > sel L2 name
SELECT IS APPROXIMATELY 63% COMPLETE
E13 THROUGH E796 ASSIGNED


= > e elastase
E797       1    ELASTAN/BI
E798       1    ELASTANE/BI
E799     552 --> ELASTASE/BI
E800       2    ELASTASIN/BI
E801       5    ELASTAT/BI
E802       4    ELASTATIN/BI
E803       3    ELASTATINAL/BI
E804       1    ELASTATINIC/BI
E805       1    ELASTATINOL/BI
E806       1    ELASTCHEM/BI
E807       1    ELASTENE/BI
E808       1    ELASTEP/BI
= > s e799
L3       552 ELASTASE/BI
L3   ANSWER 1 OF 552  REGISTRY  COPYRIGHT 2004 ACS on STN
RN   620690-36-0  REGISTRY
CN   Secretory leukocyte elastase inhibitor (human) (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   21: PN: WO03090682 SEQID: 23 claimed protein
FS   PROTEIN SEQUENCE
MF   Unspecified
```

CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
          1 REFERENCES IN FILE CA (1907 TO DATE)
          1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
= > sel L3 name
E# OR SYSTEM LIMIT REACHED WHILE PROCESSING ANSWER 83
E809 THROUGH E999 ASSIGNED

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
     BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
     CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU,
     DGENE, DRUGB, DRUGMONOG2, ...' ENTERED AT 13:35:41 ON 18 FEB 2004
= > L2
     227 FILE ADISCTI
      61 FILE ADISINSIGHT
      20 FILE ADISNEWS
     271 FILE AGRICOLA
      90 FILE ANABSTR
     196 FILE AQUASCI
     216 FILE BIOBUSINESS
      97 FILE BIOCOMMERCE
   16999 FILE BIOSIS
     571 FILE BIOTECHABS
     571 FILE BIOTECHDS
    5452 FILE BIOTECHNO
    1051 FILE CABA
    4718 FILE CANCERLIT
   14959 FILE CAPLUS
      75 FILE CEABA-VTB
       5 FILE CEN
      63 FILE CIN
     367 FILE CONFSCI
       1 FILE CROPB
      15 FILE CROPU
     576 FILE DISSABS
     286 FILE DDFB
    4240 FILE DDFU
    5657 FILE DGENE
     286 FILE DRUGB
      90 FILE DRUGMONOG2
      50 FILE IMSDRUGNEWS
    5635 FILE DRUGU
 29 FILES SEARCHED...
      35 FILE IMSRESEARCH
      62 FILE EMBAL
   15313 FILE EMBASE
    3371 FILE ESBIOBASE
     281 FILE FEDRIP
      85 FILE FROSTI
     115 FILE FSTA
    9809 FILE GENBANK
      12 FILE HEALSAFE

```
   806  FILE IFIPAT
    19  FILE IMSPRODUCT
  1634  FILE JICST-EPLUS
   124  FILE KOSMET
  2738  FILE LIFESCI
     1  FILE MEDICONF
 17615  FILE MEDLINE
   146  FILE NIOSHTIC
   100  FILE NTIS
    43  FILE OCEAN
  5496  FILE PASCAL
   107  FILE PHAR
    24  FILE PHARMAML
   110  FILE PHIN
   401  FILE PROMT
     4  FILE RDISCLOSURE
 14319  FILE SCISEARCH
     4  FILE SYNTHLINE
  6633  FILE TOXCENTER
 10854  FILE USPATFULL
   451  FILE USPAT2
     5  FILE VETB
   276  FILE VETU
 66 FILES SEARCHED...
  1378  FILE WPIDS
  1378  FILE WPINDEX
```

L4   QUE L2 63 FILES HAVE ONE OR MORE ANSWERS
L5   QUE "EC 3.4.24.3" OR(MICROBIAL COLLAGENASE) OR (CLOSTRIDIUM HISTOLYTICUM C
       OLLAGENASE) OR (CLOSTRIDIOPEPTIDASE A) OR (COLLAGENASE A) OR (COLLAGEN
       ASE I), 47 FILES HAVE ONE OR MORE ANSWERS
L6   QUE (ACHROMOBACTER IOPHAGUS COLLAGENASE) OR (COLLAGENASE) OR(ASPERGILLOPEP
       TIDASE C) OR (NUCLEOLYSIN) OR (AZOCOLLASE) OR (METALLOCOLLAGENASE) OR
       (SOYCOLLAGESTIN), 63 FILES HAVE ONE OR MORE ANSWERS
L7   QUE (MATRIX METALLOPROTEINASE-8) OR (MATIRX METALLOPROTEINASE-18) OR (INTE
       RSTITIAL COLLAGENASE) , 43 FILES HAVE ONE OR MORE ANSWERS
L8   QUE (L4 AND L5) AND (L6 AND L7) 21 FILES HAVE ONE OR MORE ANSWERS
L9   QUE "EC3.4.21.37" OR (LEUKOCYTE ELASTASE) OR (LYSOSOMAL ELASTASE) OR (NEUT
       ROPHIL ELASTASE) OR (POLYMORPHONUCLEAR LEUKOCYTE ELASTASE) OR ELASTASE
       OR ELASZYM OR (SERINE ELASTASE)   63 FILES HAVE ONE OR MORE ANSWERS
L10 QUE L3 AND L9   63 FILES HAVE ONE OR MORE ANSWERS
L11 QUE (COMPOSITION OR FORMULATION OR FORMULA#####)   68 FILES HAVE ONE OR MORE
ANSWERS
L12 QUE (TREAT OR TREAT? OR THERAPY OR THERAPEU######) 68 FILES HAVE ONE OR MORE
ANSWERS
L13 QUE (OBSTRUCTED OR BLOCKED OR CONSTRICTED) AND (?ARTERY OR VEIN OR AORTA O
       R VESSEL OR BLOOD VESSEL)   58 FILES HAVE ONE OR MORE ANSWERS
L14 QUE ATHEROSCLEROSIS OR STENOSIS OR ARTERIOSCLEROSIS OR ((OBSTRUCTED OR BLO
       CKED OR CONSTRICTED) AND (?ARTERY OR ?VEIN))   64 FILES HAVE ONE OR MORE ANSWERS
L15 QUE L13 AND L14   56 FILES HAVE ONE OR MORE ANSWERS L16 QUE (HUMAN OR MAN OR
HUMAN BEING OR HOMO SAPIENS) (5N) (PATIENT OR SUBJECT)   62 FILES HAVE ONE OR MORE
ANSWERS
L17 QUE L8 AND L10   7 FILES HAVE ONE OR MORE ANSWERS, 68 FILES SEARCHED IN STNINDEX
L18 QUE L15 AND L16   30 FILES HAVE ONE OR MORE ANSWERS
L19 QUE L12 AND L18   26 FILES HAVE ONE OR MORE ANSWERS
L20 QUE L11 AND L8   8 FILES HAVE ONE OR MORE ANSWERS
L21 QUE L11 AND L10   54 FILES HAVE ONE OR MORE ANSWERS
L22 QUE L11 AND L17   5 FILES HAVE ONE OR MORE ANSWERS
L23 QUE L19 AND L20 2 FILES HAVE ONE OR MORE ANSWERS

= > d rank
F1   19   USPATFULL
F2   1   USPAT2
L24 QUE L19 AND L21   2 FILES HAVE ONE OR MORE ANSWERS
L25 QUE L19 AND L22   2 FILES HAVE ONE OR MORE ANSWERS
= > d rank
F1   18   USPATFULL
F2   1   USPAT2
L26   3 L23 AND L24 AND L25
L27   3 DUP REM L26 (0 DUPLICATES REMOVED)
L27 ANSWER 1 OF 3 USPATFULL on STN
AB   The present invention relates to the compositions, methods,
      and applications of a novel approach to selective cellular targeting.
      The purpose of this invention is to enable the selective delivery and/or
      selective activation of effector molecules to target cells for
      diagnostic or therapeutic purposes. The present invention
      relates to multi-functional prodrugs or targeting vehicles wherein each
      functionality is capable of enhancing targeting selectivity, affinity,
      intracellular transport, activation or detoxification. The present
      invention also relates to ultra-low dose, multiple target, multiple drug
      chemotherapy and targeted immunotherapy for cancer treatment.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN   2003:200449 USPATFULL
TI   Selective cellular targeting: multifunctional delivery vehicles,
      multifunctional prodrugs, use as antineoplastic drugs
IN   Glazier, Arnold, Newton, MA, UNITED STATES
PA   Drug Innovation & Design, Inc. (U.S. corporation)
PI   US 2003138432   A1   20030724
AI   US 2000-738625   A1   20001215 (9)
RLI   Continuation of Ser. No. US 2000-712465, filed on 15 Nov 2000, ABANDONED
PRAI US 1999-165485P   19991115 (60)
      US 2000-239478P   20001011 (60)
      US 2000-241939P   20001010 (60)
DT   Utility
FS   APPLICATION
LREP N. Scott Pierce, Esq., HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two
      Militia Drive, Lexington, MA, 02421-4799
CLMN Number of Claims: 29
ECL   Exemplary Claim: 1
DRWN No Drawings
LN.CNT 18716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 2 OF 3 USPATFULL on STN
AB   Invasive remodelling in a mammal may be inhibited by (1) inhibiting or
      abolishing the protein cleaving action of plasmin and (2) inhibiting or
      abolishing the protein cleaving action of at least one additional
      proteolytic enzyme active in invasive remodelling, such as a
      metalloprotease.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN   2002:186083 USPATFULL
TI   Inhibition of invasive remodelling
IN   Lund, Leif Roge, Copenhagen, DENMARK
      Dano, Keld, Charlottenlund, DENMARK
      Stephens, Ross, Charlottenlund, DENMARK
      Brunner, Nils, Hellerup, DENMARK
      Solberg, Helene, Hillerod, DENMARK
      Holst-Hansen, Claus, Frederiksberg C, DENMARK

Nielsen, John Romer, Copenhagen O, DENMARK
PI   US 2002099004   A1   20020725
AI   US 2001-995636   A1   20011129 (9)
RLI   Continuation of Ser. No. US 1999-319464, filed on 27 Aug 1999, ABANDONED
      A 371 of International Ser. No. WO 1997-DK555, filed on 8 Dec 1997,
      UNKNOWN
PRAI DK 1996-1402   19961206
DT   Utility
FS   APPLICATION
LREP BROWDY AND NEIMARK, P.L.L.C., 624 Ninth Street, N.W., Washington, DC,
      20001
CLMN Number of Claims: 39
ECL   Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2781
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L27 ANSWER 3 OF 3 USPATFULL on STN
AB   Disclosed are various compositions and methods for use in
      achieving specific blood coagulation. This is exemplified by the
      specific in vivo coagulation of tumor vasculature, causing tumor
      regression, through the site-specific delivery of a coagulant using a
      bispecific antibody.
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN   1999:27746 USPATFULL
TI   Tissue factor compositions and ligands for the specific
      coagulation of vasculature
IN   Thorpe, Philip E., Dallas, TX, United States
      Edgington, Thomas S., La Jolla, CA, United States
PA   The Scripps Research Institute, La Jolla, CA, United States (U.S.
      corporation)
      Board of Regents, The University of Texas System, Austin, TX, United
      States (U.S. corporation)
PI   US 5877289   19990302
AI   US 1995-479733   19950607 (8)
RLI   Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994
      which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2
      Mar 1994, now patented, Pat. No. US 5855866 which is a
      continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992
DT   Utility
FS   Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Arnold White & Durkee L.L.P.
CLMN Number of Claims: 100
ECL   Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 7148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L28   1 L27 NOT PY > 1999
L28 ANSWER 1 OF 1 USPATFULL on STN
AB   Disclosed are various compositions and methods for use in
      achieving specific blood coagulation. This is exemplified by the
      specific in vivo coagulation of tumor vasculature, causing tumor
      regression, through the site-specific delivery of a coagulant using a
      bispecific antibody.
  CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN   1999:27746 USPATFULL
TI   Tissue factor compositions and ligands for the specific
      coagulation of vasculature
IN   Thorpe, Philip E., Dallas, TX, United States
      Edgington, Thomas S., La Jolla, CA, United States
PA   The Scripps Research Institute, La Jolla, CA, United States (U.S.
      corporation)
      Board of Regents, The University of Texas System, Austin, TX, United
      States (U.S. corporation)
PI   US 5877289   19990302
AI   US 1995-479733   19950607 (8)
RLI   Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994
      which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2
      Mar 1994, now patented, Pat. No. US 5855866 which is a
      continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992
DT   Utility
FS   Granted
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Arnold White & Durkee L.L.P.
CLMN Number of Claims: 100
ECL   Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)
LN.CNT 7148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The Contents of Case 09669051US_02182004

Qnum	Query	DB Name	Thesaurus	Operator	Plural
Q1	(((424/94.64)!.CCLS.)) and @pd > 20030401	USPT	None	ADJ	YES
Q2	((((424/423)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q3	((((424/424)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q4	((((424/425)!.CCLS.))) and @pd > 20030401	USPT	None	ADJ	YES
Q5	(Q1 and Q4) and @pd > 20030401	USPT	None	ADJ	YES
Q6	(Q2 and Q4) and @pd > 20030401	USPT	None	ADJ	YES
Q7	(Q3 and Q6) and @pd > 20030401	USPT	None	ADJ	YES
Q8	(Q1 and Q7) and @pd > 20030401	USPT	None	ADJ	YES
Q9	(Q1 and Q2) and @pd > 20030401	USPT	None	ADJ	YES
Q10	(Q3 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q11	(Q6 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q12	(Q4 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q13	(Q7 and Q9) and @pd > 20030401	USPT	None	ADJ	YES
Q14	(514/1) and @pd > 20030401	USPT	None	ADJ	YES
Q15	(514/12) and @pd > 20030401	USPT	None	ADJ	YES
Q16	(514/21) and @pd > 20030401	USPT	None	ADJ	YES
Q17	(514/232.5) and @pd > 20030401	USPT	None	ADJ	YES
Q18	(514/232.8) and @pd > 20030401	USPT	None	ADJ	YES
Q19	(514/234.8) and @pd > 20030401	USPT	None	ADJ	YES
Q20	(514/255) and @pd > 20030401	USPT	None	ADJ	YES
Q21	(514/259) and @pd > 20030401	USPT	None	ADJ	YES
Q22	(514/319) and @pd >	USPT	None	ADJ	YES

Q23	20030401 (514/324) and @pd > 20030401	USPT	None	ADJ	YES
Q24	(514/411) and @pd > 20030401	USPT	None	ADJ	YES
Q25	(514/422) and @pd > 20030401	USPT	None	ADJ	YES
Q26	(514/428) and @pd > 20030401	USPT	None	ADJ	YES
Q27	(514/429) and @pd > 20030401	USPT	None	ADJ	YES
Q28	(514/441) and @pd > 20030401	USPT	None	ADJ	YES
Q29	(514/449) and @pd > 20030401	USPT	None	ADJ	YES
Q30	(514/473) and @pd > 20030401	USPT	None	ADJ	YES
Q31	(Q29 and Q30) and @pd > 20030401	USPT	None	ADJ	YES
Q32	(Q28 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q33	(Q27 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q34	(Q26 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q35	(Q25 and Q31) and @pd > 20030401	USPT	None	ADJ	YES
Q36	(Q14 and Q15) and @pd > 20030401	USPT	None	ADJ	YES
Q37	(Q16 and Q36) and @pd > 20030401	USPT	None	ADJ	YES
Q38	(Q9 and Q37) and @pd > 20030401	USPT	None	ADJ	YES
Q39	(Q17 and Q18) and @pd > 20030401	USPT	None	ADJ	YES
Q40	(Q19 and Q39) and @pd > 20030401	USPT	None	ADJ	YES
Q41	(Q20 and Q21) and @pd > 20030401	USPT	None	ADJ	YES
Q42	(Q41 and Q22) and @pd > 20030401	USPT	None	ADJ	YES
Q43	(Q23 and Q42) and @pd > 20030401	USPT	None	ADJ	YES
Q44	(Q24 and Q43) and @pd > 20030401	USPT	None	ADJ	YES
Q45	(Q24 and Q25) and @pd > 20030401	USPT	None	ADJ	YES
Q46	(Q26 and Q45) and @pd > 20030401	USPT	None	ADJ	YES
	(Q27 and Q46) and				

Q47	@pd > 20030401	USPT	None	ADJ	YES
Q48	(Q28 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q49	(Q29 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q50	(Q30 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q51	(Q31 and Q47) and @pd > 20030401	USPT	None	ADJ	YES
Q52	(Q31 and Q7) and @pd > 20030401	USPT	None	ADJ	YES
Q53	(Q31 and 40) and @pd > 20030401	USPT	None	ADJ	YES
Q54	(Q7 and Q53) and @pd > 20030401	USPT	None	ADJ	YES
Q55	(((biological conduit or artery or vasculature) same (human or mammal or animal)) near5 ((dilat$5 or open or de-obstruct)near5 (collagenase or protease or collagen degrading enzyme))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q56	(((biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 ((dilat$5 or open or de-obstruct)near5 (collagenase or protease or collagen degrading enzyme))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q57	(((biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat$5 or open or de-obstruct)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q58	(((stenosis or biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat$5 or open or de-obstruct)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

h   e h   e   e   e   e e f e   e   c e

Q59	((collagenase or protease or collagen degrading enzyme)) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q60	(Q58 and Q59) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q61	((collagenase or protease) near5 (((stenosis or biological conduit or artery or vasculature) near5 (human or mammal or animal)) near5 (dilat$5 or open or de-obstruct))) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q62	(collagenase or collagen degrading enzyme or collagen hydrolyzing enzyme) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q63	(Q62 and Q59) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES
Q64	(Q58 and Q63) and @pd > 20030401	USPT,PGPB,JPAB,EPAB,DWPI	None	ADJ	YES

Case Operation

Run Case ▼

Submit   Cancel